top of page

All News:

Bob Enck 1200px.jpg

Recent News

Monday, February 5th 2024

As part of a planned transition aimed at strengthening our leadership with a focus  on robust commercial growth in the Diagnostics and Sample Preparation industries, we are pleased to announce the appointment of Bob Enck, current Chairman and President, as CEO. 


Recent News

Thurs, December 21st 2023

ProtonDx’s Regulatory Affairs Director, Dr Kasia Szostak-Lipowicz, was invited to the UN Panel on Transformative Digital Diagnostic Technologies, where she discussed how ProtonDx’s work can help bridge healthcare gaps in Africa.

Screen Shot 2023-07-21 at 1.40.56 PM.png

Recent News

Thurs, November 2nd 2023

POCT-for-Scot Ltd. completed an evaluation of ProtonDx's multi-pathogen Dragonfly Respiratory diagnostic device. The study delves into the feasibility of using Dragonfly in Point-of-Care settings and provides insights into adoption by POC clinics! 

Jesus Rodriguez Manzano-475_edited.jpg

Recent News

Thurs, October 19th 2023

Dr Rodriguez Manzano's promotion to Associate Professor in the Department of Infectious Disease at Imperial College London showcases his dedication to advancing the field of Molecular Diagnostics, with a particular focus on addressing infections and antimicrobial resistance (AMR).


Recent News

Tue, September 27th 2023

ProtonDx's Dragonfly Respiratory Panel, a portable, accurate, and rapid diagnostic device, played a pivotal role in maintaining the health and performance of UK team members throughout the Tour de France 2023.

Recent News

Tue, March 28th 2023

ProtonDx's proprietary rapid multipathogen test was a key diagnostic element used to test the Finnish cross-country skiers in The FIS Nordic World Ski Championships in Planica, Slovenia, in February - March 2023.

Company Announcements

ProtonDx Welcomes New CFO, Ann Wong, to Drive Scale-up and Commercial Expansion

Thu, March 16th 2023

Ann Wong brings extensive experience of scaling organisations and leading finance operations. 

Company Announcements

Dragonfly Respiratory Panel Reliably Identifies Five Most Common Causes of Respiratory Infections, Joins List of UK Approved Diagnostic Products

Mon, February 6th 2023

Rapid molecular point-of-care diagnostic system reliably detects SARS-CoV-2, Flu A, Flu B, RSV and Human Rhinovirus. Clinical test results for CTDA validation achieved 100% sensitivity and 100% specificity. UK approval follows CE-IVD mark.

Company Announcements

ProtonDx and Katalyst Announce Strategic Partnership to Distribute Dragonfly in Vitro Diagnostic

Mon, January 9th 2023

Exclusive rights to distribute CE-IVD marked Dragonfly diagnostic system in key client segments. Dragonfly System able to detect five common respiratory pathogens at once.


The Respiratory Infection Season – Multiple Infections, Multiple Detection

Mon, December 12th 2022

Assistant Professor Jesus Rodriguez Manzano, Co-Founder and CSO at ProtonDx, and Deputy Director of the Centre for Antimicrobial Optimisation (CAMO) at Imperial College, shares his views on the current threat of a ‘tripledemic’ that looms over the Northern hemisphere, including many parts of Europe.

Company Announcements

ProtonDx Awarded £365,000 Defra and Innovate UK Grant to Develop Porcine Lung Disease Diagnostic

Fri, September 23rd 2022

Grant to develop automated, rapid point-of-need diagnostic to provide a sustainable and resilient revolution in detection and diagnosis of Porcine Respiratory Disease Complex (PRDC). Working in collaboration with Imperial College, farmers and industry experts to help address the global issue of rising antibiotic resistance.


Diagnostics are at the Heart of a Global AMR Solution

Wed, September 14th 2022

OPINION: Dr Jesus Rodriguez-Manzano, Co-Founder and Chief Scientific Officer (CSO) at ProtonDx, shares his thoughts on anti-microbial resistance (AMR). He discusses what we can learn from the recent COVID‑19 pandemic, including the important role that point-of-need diagnostics can play.

Company Announcements

ProtonDx’s Dragonfly Diagnostic System Successfully Deployed at the 2022 Commonwealth Games

Tue, August 30th 2022

5-in-1 Respiratory Test Panel from ProtonDx used to assess elite athletes at the 2022 Commonwealth Games.

Company Announcements

New Rapid Multi-Viral Diagnostic Kit Receives CE-IVD Mark

Tue, June 21st 2022

Dragonfly™ detects SARS-CoV-2, Flu A, Flu B, RSV and human rhinovirus without a lab. It is a cost-effective point-of-need portable diagnostic system for infectious disease now commercially available.

Company Announcements

ProtonDx Tackles Malaria Diagnosis

Fri, April 29th 2022

Lacewing, the futuristic lab-on-a-chip, diagnostic tool is one of eight initiatives promoted by Imperial College London to mark Malaria Day, 25 April, in order to demonstrate the College’s deep commitment to conquering malaria. Lacewing is being developed for health care applications by Imperial spin out company ProtonDx based at the College’s Translation and Innovation HUB (I-HUB), White City Campus.

Company Announcements

Dragonfly Goes Olympic

Tue, April 26th 2022

The Dragonfly Respiratory Diagnostic Panel was utilised by the Team GB clinical staff with great success to test Great Britain's athletes at the 2022 Olympic Winter Games in Beijing.


Higher Risk for Patients with Flu and Covid-19

Mon, March 28th 2022

People infected by Covid-19 and influenza face four times the risk of requiring a ventilator and twice the risk of death. Diagnosis of which respiratory viruses are infecting the patient is crucial especially as there is no increased risk of severe illness for those with both Covid-19 and RSV or other respiratory viruses.


Lateral Flow Tests Found Wanting

Tue, March 1st 2022

Research by Imperial College London suggests that lateral flow tests miss a substantial number of COVID-19 infections, particularly for people without symptoms emphasising the need for rapid, sensitive, accurate and portable tests.


Antimicrobial Resistance Crisis Needs Better Diagnostics

Tue, February 22nd 2022

“Better, faster diagnostics will be central to tackling Antimicrobial Resistance in the future,” said ProtonDx Founder & Director, Asst Professor Jesus Rodriguez-Manzano, at a recent FORUM event organised by the Academy of Medical Sciences.

Company Announcements

ProtonDx CEO Award for Inspiration

Mon, December 20th 2021

ProtonDx CEO, Professor Pantelis Georgiou has won an award for his inspirational work from his colleagues in the Department of Electrical and Electronic Engineering, Imperial College London

Company Announcements

Imperial Biomedical Hub Officially Opened

Mon, December 6th 2021

ProtonDx is privileged to have secured office space in the prestigious Translation and Innovation Hub (IHUB) at White City campus of Imperial College London.

Company Announcements

Best of British Recognises ProtonDx

Thu, September 23rd 2021

The work of the ProtonDx team has been recognized in Best of British a government publication produced jointly with Malaria NO MORE.

Company Announcements

ProtonDx CEO Appointed Professor of Biomedical Electronics

Wed, September 22nd 2021

CEO of ProtonDx, Dr Pantelis Georgiou, was promoted to Professor of Biomedical Electronics in the annual promotion round at Imperial College London, one of only six to achieve this accolade this year.  

bottom of page